Get the Stockscreener App
9.72
13.29%
-1.49
Cyclacel Pharmaceuticals Inc stock is traded at $9.72, with a volume of 144.57K.
It is down -13.29% in the last 24 hours and up +2,790% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$11.21
Open:
$10.76
24h Volume:
144.57K
Relative Volume:
0.05
Market Cap:
$15.40M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-1.034
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-39.40%
1M Performance:
+2,790%
6M Performance:
+82.43%
1Y Performance:
-63.18%
1-Day Range:
$9.50
$10.93
1-Week Range:
$9.50
$16.28
52-Week Range:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
9.72 | 17.81M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyBreakout Stocks Signals For Fast Growth - jammulinksnews.com
Using Python tools to backtest Cyclacel Pharmaceuticals Inc. strategiesMomentum Trading Guide with Safety Limits - Newser
What Technical Tools Say About Cyclacel Pharmaceuticals Inc. RecoveryFast Entry High Potential Stock Alerts Triggered - metal.it
How high can Cyclacel Pharmaceuticals Inc. stock goAI Trade Signal Forecast with Chart Logic - Newser
Custom strategy builders for tracking Cyclacel Pharmaceuticals Inc.Free Daily Momentum Screener With Alerts - Newser
Cyclacel Pharmaceuticals Inc. recovery potential after sell offWeekly Gain Forecast with Momentum Indicators - Newser
Full technical analysis of Cyclacel Pharmaceuticals Inc. stockProven Trading System with Consistent Gains - Newser
What the charts say about Cyclacel Pharmaceuticals Inc. todayConservative Asset Allocation Risk Analysis - Newser
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionReal-Time Entry Signals for Top Stocks - Newser
Is Cyclacel Pharmaceuticals Inc. Starting a New UptrendSector Based Breakout Stock Forecast Issued - metal.it
Cyclacel Pharmaceuticals Amends Series F Stock Limitations - TipRanks
How strong is Cyclacel Pharmaceuticals Inc. company’s balance sheetExpert Picks Tips With High Returns - jammulinksnews.com
What institutional investors are buying Cyclacel Pharmaceuticals Inc. stockMarket-leading growth rates - jammulinksnews.com
What are Cyclacel Pharmaceuticals Inc. company’s key revenue driversFree Consultation - jammulinksnews.com
What are the latest earnings results for Cyclacel Pharmaceuticals Inc.Achieve superior capital gains with smart trades - jammulinksnews.com
What is the risk reward ratio of investing in Cyclacel Pharmaceuticals Inc. stockUnlock daily market insights for better decisions - jammulinksnews.com
Does Cyclacel Pharmaceuticals Inc. stock perform well during market downturnsHigh-profit stock alerts - jammulinksnews.com
When is Cyclacel Pharmaceuticals Inc. stock expected to show significant growthInvest confidently with proven investment plans - jammulinksnews.com
What are analysts’ price targets for Cyclacel Pharmaceuticals Inc. in the next 12 monthsGet professional advice for market timing - jammulinksnews.com
Is Cyclacel Pharmaceuticals Inc. stock overvalued or undervaluedDynamic investment growth - jammulinksnews.com
Should I hold or sell Cyclacel Pharmaceuticals Inc. stock in 2025Track stocks with high upside potential easily - jammulinksnews.com
Competitive Positioning of Cyclacel Pharmaceuticals Inc.: Is It Leading or LaggingCapital Safe Smart Trades - Newser
What analysts say about Cyclacel Pharmaceuticals Inc. stockSuperior investment outcomes - PrintWeekIndia
Is Cyclacel Pharmaceuticals Inc. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY - ADVFN Brasil
How Cyclacel Pharmaceuticals Inc. stock reacts to Fed policy changesFree Trading Psychology Coaching - jammulinksnews.com
What drives Cyclacel Pharmaceuticals Inc. stock priceExponential wealth increase - Autocar Professional
Is Cyclacel Pharmaceuticals Inc. stock overhyped or has real potentialDynamic investment opportunities - jammulinksnews.com
Cyclacel Pharmaceuticals Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - Autocar Professional
Cyclacel Pharmaceuticals (CYCC) Soars 67.76% on Cancer Therapy Hopes - AInvest
Cyclacel Explodes 31.23%—Is This the Catalyst for a Biotech Resurgence? - AInvest
(CYCCP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
CYCC’s Financial Health: Exploring Cyclacel Pharmaceuticals Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):